[Neuroendocrine differentiation in breast cancer]

Area of Science:

• Oncology
• Pathology
• Endocrinology

Background:

• Neuroendocrine differentiation (NED) in breast cancer shares features with gastrointestinal and lung neuroendocrine tumors (NET).
• Accurate classification of breast cancer with NED is essential for prognosis and treatment, though its clinical relevance is debated.
• The upcoming WHO classification will introduce a new category: NET luminal type.

Purpose of the Study:

• To define the criteria for classifying breast cancer with neuroendocrine differentiation.
• To differentiate between primary breast NET and metastatic NET.
• To clarify the diagnostic challenges and implications of NED in breast pathology.

Main Methods:

• Histopathological analysis of breast cancer tissue.
• Immunohistochemical staining for neuroendocrine markers (chromogranin, synaptophysin) and GATA3.
• Evaluation of tumor growth patterns and differentiation grade (G1, G2).

Main Results:

• Breast cancers with NED typically exhibit hormone receptor positivity and resemble luminal-type breast cancer.
• Immunohistochemical detection of neuroendocrine markers alone is insufficient for classification.
• Poorly differentiated NET, including small cell types, require careful differentiation from well-differentiated NET and metastatic disease.

Conclusions:

• Classification of breast cancer with NED necessitates specific growth patterns and immunohistochemical markers.
• Distinguishing primary breast NET from metastatic disease requires correlation with clinical findings and assessment of GATA3 co-expression.
• While a new category is proposed, the clinical significance of NED in breast cancer requires further investigation.